Skip to content


The seminar held at AstraZeneca forms part of a Swedish Research Institute (RISE) pilot on the ATMP field in Sweden.

Dr Daniel C Smith, Chief Scientific Officer Cobra Biologics, has been invited to present an overview of Cobra's capabilities in the ATMP field and provide an update on the company's 165mSEK gene therapy manufacturing operations expansion plans.

Arrange to meet with Daniel Smith and Magnus Gustafsson, Business and Corporate Development Director Cobra Biologics, in Gothenburg using the simple form below.

Arrange your meeting

Fields marked * are required

Arrange your meeting

This website uses cookies. For more information about these please click here.
By continuing to browse you consent to the use of cookies